- Publications
- Influence
Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications.
- Hannes Wandt, Margareta Frank, +16 authors H. Link
- Blood
- 1998
In 105 consecutive patients with de novo acute myeloid leukemia (French-American-British M3 excluded), we compared prospectively the risk of bleeding complications, the number of platelet and red… (More)
- Elke Jäger, Salah-Eddin Al-Batran, +7 authors Nadia Harbeck
- 2010
1022 Background: PLD and CAP have significant antitumor activity in a wide range of solid tumors including MBC. The PELICAN trial was designed to compare efficacy and safety of first-line PLD vs. CAP… (More)
- G. Huebner, Hartmut Link, +15 authors Albrecht Jahn
- British Journal of Cancer
- 2009
Platinum/taxane combinations are widely used in patients with carcinoma of unknown primary (CUP), yielding response rates of 30% and median overall survival of 9–11 months in selected patients. Yet… (More)
- Friedemann Honecker, Nadia Harbeck, +12 authors Maike de Wit
- Journal of geriatric oncology
- 2017
OBJECTIVES
To determine predictive/prognostic factors for patients with metastatic breast cancer (MBC) receiving first-line monochemotherapy using biomarker analysis and geriatric assessment (GA).
… (More)
- Rachel Wuerstlein, Karl Sotlar, +17 authors Nadia Harbeck
- Current medical research and opinion
- 2016
PURPOSE
The West German Study Group (WSG) Breast Cancer Intrinsic Subtype (BCIST) study was designed to assess the influence of Prosigna gene signature assay results on physicians' adjuvant treatment… (More)
- Jalid Sehouli, Oumar Camara, +8 authors on behalf of the North-Eastern German Society of Gyne Oncology
- Cancer Chemotherapy and Pharmacology
- 2008
PurposePegylated liposomal doxorubicin (PLD, CAELYX®) has demonstrated activity in several phase-III trials and has been approved for the therapy of relapsed ovarian cancer after platinum treatment.… (More)
- Elodie Elkaim, Bénédicte Neven, +40 authors Sven Kracker
- 2016
Background: Activated phosphoinositide 3-kinase delta syndrome (APDS) 2 ă (p110 delta-activating mutations causing senescent T cells, ă lymphadenopathy, and immunodeficiency [PASLI]-R1), a recently ă… (More)
- Nadia Harbeck, Steffen Saupe, +17 authors Salah-Eddin Al-Batran
- Breast Cancer Research and Treatment
- 2016
PurposeThe PELICAN trial evaluates for the first time efficacy and safety of pegylated liposomal doxorubicin (PLD) versus capecitabine as first-line treatment of metastatic breast cancer… (More)
- Radoslav Chekerov, Guelten Oskay-Oezcelik, +6 authors Jalid Sehouli
- 2008
16552 Background: Pegylated liposomal doxorubicin (PLD) has demonstrated activity and been approved for the treatment of platinum-pretreated relapsed ovarian cancer when given at a dose of 50 mg/m2...
- Rachel Wuerstlein, Karl Sotlar, +17 authors Nadia Harbeck
- 2015
535 Background: Prosigna is a standardized test measuring expression levels of 50 classifier genes (PAM50) in formalin-fixed, paraffin-embedded (FFPE) breast tumor tissue using nCounter Technology… (More)